The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status

Journal of Lipid Research

Volumn 46, Issue 9, 2005, Pages 1888-1895

  Rozek, Laura S ^a,b   Hatsukami, Thomas S ^c   Richter, Rebecca J ^b   Ranchalis, Jane ^b   Nakayama, Karen ^b   McKinstry, Laura A ^b   Gortner, David A ^d   Boyko, Edward ^c   Schellenberg, Gerard D ^b,c   Furlong, Clement E ^b   Jarvik, Gail P ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Veterans Puget Sound Health Care System   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein A I; Carotid artery disease; Lipoprotein; Paraoxonase; Transcription

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CAROTID ARTERY DISEASE; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE LOCUS; GENOTYPE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 24344487196     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400489-JLR200     Document Type: Article

References (63)

1. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
2. Mackness, M. I. 1994. The human paraoxonase polymorphism and atherosclerosis. In Esterases, Lipases, and Phospholipases. M. I. Mackness and M. Cleric, editors. Plenum Press, New York. 65-73.
3. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Fuall, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
4. Graham, A., D. G. Hassall, S. Rafique, and J. S. Owen. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135: 193-204.
5. Chemnitius, J. M., H. Winkel, I. Meyer, K. Schirrmacher, V. W. Armstrong, H. Kreuzer, and R. Zech. 1998. Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease. Med. Klin. (Munich). 93: 137-145.
6. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26: 892-904.
7. Bergmeier, C., R. Siekmeier, and W. Gross. 2004. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50: 2309-2315.
8. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330-335.
9. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1 (55) genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
10. Mackness, B., K. D. Gershan, W. Turkie, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. Durrington, and M. Mackness. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21: 1451-1457.
11. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003a. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471.
12. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
13. Robertson, K. S., E. Hawe, G. J. Miller, P. J. Talmud, and S. E. Humphries. 2003. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim. Biophys. Acta. 1639: 203-212.
14. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
15. Rozenberg, O., M. Rosenblat, R. Coleman, D. M. Shih, and M. Aviram. 2003. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
16. Tward, A., Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484-490.
17. Playfer, J. R., L. C. Eze, M. F. Bullen, and D. A. P. Evans. 1976. Genetic polymorphism and inter-ethnic variability of plasma paraoxonase activity. J. Med. Genet. 13: 337-342.
18. Furlong, C. E., R. J. Richter, S. L. Seidel, and A. G. Motulsky. 1988. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am. J. Hum. Genet. 43: 230-238.
19. Brophy, V. H., G. P. Jarvik, R. J. Richter, L. S. Rozek, G. D. Schellenberg, and C. E. Furlong. 2000. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics. 10: 453-460.
20. Davies, H., R. J. Richter, M. Keifer, C. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat. Genet. 14: 334-336.
21. Eckerson, H. W., C. M. Wyte, and B. N. La Du. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35: 1126-1138.
22. Mackness, M., and B. Mackness. 2004. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic. Biol. Med. 37: 1317-1323.
23. Lohmueller, K. E., C. L. Pearce, M. Pike, E. S. Lander, and J. N. Hirschhorn. 2003. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33: 177-182.
24. Wheeler, J. G., B. D. Keavney, H. Watkins, R. Collins, and J. Danesh. 2004a. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 363: 689-695.
25. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
26. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
27. [Erratum 1991. FEBS Lett. 292: 307.]
28. Mackness, B., D. Hine, Y. Liu, M. Mastorikou, and M. Mackness. 2004. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318: 680-683.
29. Mackness, B., M. I. Mackness, S. Arrol, W. Turkic, and P. N. Durrington. 1998. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.
30. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998a. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
31. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
32. Oda, M. N., J. K. Biellcki, T. T. Ho, T. Berger, E. M. Rubin, and T. M. Forte. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290: 921-927.
33. Deakin, S., I. Leviev, S. Guernier, and R. W. James. 2003. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23: 2083-2089.
34. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
35. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
36. Brophy, V. H., M. D. Hastings, J. B. Clendenning, R. Richter, G. P. Jarvik, and C. E. Furlong. 2001a. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84.
37. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001b. Promoter polymorphism effects on paraoxonase (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436.
38. Furlong, C. E., R. J. Richter, S. L. Seidel, L. G. Costa, and A. G. Motulsky. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/ arylesterase. Anal. Biochem. 180: 242-247.
39. Richter, R. J., and C. E. Furlong. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745-753.
40. Jarvik, G. P., R. Jampsa, R. J. Richter, C. S. Carlson, M. J. Rieder, D. A. Nickerson, and C. E. Furlong. 2003b. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291-295.
41. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density- lipoprotein cholesterol. Clin. Chem. 28: 1379-1388.
42. Bachorik, P. S., and J. J. Albers. 1986. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 129: 78-100.
43. Warnick, G. R. 1986. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129: 101-123.
44. Marcovina, S. M., J. J. Albers, L. O. Henderson, and W. H. Hannon. 1993. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin. Chem. 39: 773-781.
45. Zambon, A., M. A. Austin, B. G. Brown, J. E. Hokanson, and J. D. Brunzell. 1993. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler. Thromb. 13: 147-153.
46. Auwerx, J. H., C. A. Marzetta, J. E. Hokanson, and J. D. Brunzell. 1989. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 9: 319-325.
47. SPSS. 1991. SPSS Statistical Algorithms. SPSS, Inc., Chicago, IL.
48. Tomas, M., M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat. 2000. Effect of simvastatin therapy on paraoxonase activity and related properties in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 2113-2119.
49. Suehiro, T., T. Nakamura, M. Inoue, T. Shiinoki, Y. Ikeda, Y. Kumon, M. Shindo, H. Tanaka, and K. Hashimoto. 2000. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 150: 295-298.
50. Osaki, F., Y. Ikeda, T. Suehiro, K. Ota, S. Tsuzura, K. Arii, Y. Kumon, and K. Hashimoto. 2004. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis. 176: 279-287.
51. Talianidis, I., A. Tambakaki, J. Toursounova, and V. I. Zannis. 1995. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry. 34: 10298-10309.
52. Miserez, A. R., P. Y. Muller, L. Barella, S. Barella, H. B. Staehelin, E. Leitersdorf, J. D. Kark, and Y. Friedlander. 2002. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis. 164: 15-26.
53. Duan, X., W. Zhu, Z. Zhang, Y. Zhao, J. Dao, Y. Li, and Y. Xiao. 2004. The 1784 G > C polymorphism of sterol regulatory element binding protein-2 gene: prevalence and effect on serum lipid concentrations in hyperlipidemic individuals from China. J. Lipid Res. Epub ahead of print. November 16, 2004; doi: 10.1194/jlr.M400166-JLR200.
54. Rodriguez, C., B. Raposo, J. Martinez-Gonzalez, V. Llorente-Cortes, G. Vilahur, and L. Badimon. 2003. Modulation of ERG25 expression by LDL in vascular cells. Cardiovasc. Res. 58:178-185.
55. Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R. W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277: 4301-4308.
56. Deakin, S., X. Moren, and R. W. James. 2005. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis. 179: 17-25.
57. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
58. Nevin, D., A. Zambon, C. E. Furlong, R. Richter, R. Humbert, J. E. Hokanson, and J. D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity and HDL. Arterioscler. Thromb. Vasc. Biol. 16: 1243-1249.
59. Saha, N., A. C. Roy, S. H. Teo, J. S. Tay, and S. S. Ratnam. 1991. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin. Genet. 40: 277-282.
60. Hegele, R. A., J. H. Brunt, and P. W. Connelly. 1995b. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15: 89-95.
61. Agachan, B., H. Yilmaz, Z. Karaali, and T. Isbir. 2004. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem. Fund. 22: 163-168.
62. Malin, R., S. Lehtinen, P. Luoma, S. Nayha, J. Hassi, T. Koivula, and T. Lehtimaki. 2001. Serum lipid levels and M/L55 allele distribution of HDL paraoxonase gene in Saami and Finnish men. Int. J. Circumpolar Health. 60: 16-24.
63. Fanella, S., S. B. Harris, T. K. Young, A. J. Hanley, B. Zinman, P. W. Connelly, and R. A. Hegele. 2000. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin. Chem. Lab. Med. 38: 413-420.